170 related articles for article (PubMed ID: 34143816)
41. Expanded strain coverage for a highly successful public health tool: Prophylactic 9-valent human papillomavirus vaccine.
Zhang Z; Zhang J; Xia N; Zhao Q
Hum Vaccin Immunother; 2017 Oct; 13(10):2280-2291. PubMed ID: 28699820
[TBL] [Abstract][Full Text] [Related]
42. Epidemiology of Any and Vaccine-Type Anogenital Human Papillomavirus Among 13-26-Year-Old Young Men After HPV Vaccine Introduction.
Chandler E; Ding L; Gorbach P; Franco EL; Brown DA; Widdice LE; Bernstein DI; Kahn JA
J Adolesc Health; 2018 Jul; 63(1):43-49. PubMed ID: 30060856
[TBL] [Abstract][Full Text] [Related]
43. HPV genotype prevalence in Australian women undergoing routine cervical screening by cytology status prior to implementation of an HPV vaccination program.
Tabrizi SN; Brotherton JM; Stevens MP; Condon JR; McIntyre P; Smith D; Garland SM;
J Clin Virol; 2014 Jul; 60(3):250-6. PubMed ID: 24854516
[TBL] [Abstract][Full Text] [Related]
44. A single dose of quadrivalent human papillomavirus (HPV) vaccine is immunogenic and reduces HPV detection rates in young women in Mongolia, six years after vaccination.
Batmunkh T; Dalmau MT; Munkhsaikhan ME; Khorolsuren T; Namjil N; Surenjav U; Toh ZQ; Licciardi PV; Russell FM; Garland SM; Mulholland K; von Mollendorf C
Vaccine; 2020 Jun; 38(27):4316-4324. PubMed ID: 32387009
[TBL] [Abstract][Full Text] [Related]
45. Prevalence of HPV After Introduction of the Vaccination Program in the United States.
Markowitz LE; Liu G; Hariri S; Steinau M; Dunne EF; Unger ER
Pediatrics; 2016 Mar; 137(3):e20151968. PubMed ID: 26908697
[TBL] [Abstract][Full Text] [Related]
46. Spotlight on quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine(Gardasil®) in the prevention of premalignant genital lesions, genital cancer, and genital warts in women.
McCormack PL; Joura EA
BioDrugs; 2011 Oct; 25(5):339-43. PubMed ID: 21942919
[TBL] [Abstract][Full Text] [Related]
47. Prevalence and distribution of human papillomavirus genotype in south eastern Italy, in the period 2006-2011: implications for intervention.
Guido M; Tinelli A; De Donno A; Bruno AR; Tagliaferro L; Fedele A; Carbone A; Menegazzi P; Aprile V; Greco M; Malvasi A; Piccinni MA; Turano S; Grima P; Dell' Ederam D; Zizza A
Curr Pharm Des; 2013; 19(8):1498-507. PubMed ID: 23016783
[TBL] [Abstract][Full Text] [Related]
48. Prevalence of high-risk human papillomavirus infection among women in Shaanxi province of China: A hospital-based investigation.
Cao D; Zhang S; Zhang Q; Wei X; Zhao M; Ma Q; Li Y; Wang L; Pei M; Yang T; Zhao J; Yang X
J Med Virol; 2017 Jul; 89(7):1281-1286. PubMed ID: 27935120
[TBL] [Abstract][Full Text] [Related]
49. Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (Gardasil®): a review of its use in the prevention of premalignant genital lesions, genital cancer and genital warts in women.
McCormack PL; Joura EA
Drugs; 2010 Dec; 70(18):2449-74. PubMed ID: 21142263
[TBL] [Abstract][Full Text] [Related]
50. HPV prevalence and genotype distribution in a population-based split-sample study of well-screened women using CLART HPV2 human papillomavirus genotype microarray system.
Bonde J; Rebolj M; Ejegod DM; Preisler S; Lynge E; Rygaard C
BMC Infect Dis; 2014 Jul; 14():413. PubMed ID: 25064473
[TBL] [Abstract][Full Text] [Related]
51. Prevalence of Vaccine Type Infections in Vaccinated and Non-Vaccinated Young Women: HPV-IMPACT, a Self-Sampling Study.
Jeannot E; Viviano M; de Pree C; Amadane M; Kabengele E; Vassilakos P; Petignat P
Int J Environ Res Public Health; 2018 Jul; 15(7):. PubMed ID: 29987255
[TBL] [Abstract][Full Text] [Related]
52. High prevalence of cervical high-risk human papillomavirus infection mostly covered by Gardasil-9 prophylactic vaccine in adult women living in N'Djamena, Chad.
Mboumba Bouassa RS; Nodjikouambaye ZA; Sadjoli D; Adawaye C; Péré H; Veyer D; Matta M; Robin L; Tonen-Wolyec S; Moussa AM; Koyalta D; Belec L
PLoS One; 2019; 14(6):e0217486. PubMed ID: 31158254
[TBL] [Abstract][Full Text] [Related]
53. Next-generation sequencing of cervical DNA detects human papillomavirus types not detected by commercial kits.
Meiring TL; Salimo AT; Coetzee B; Maree HJ; Moodley J; Hitzeroth II; Freeborough MJ; Rybicki EP; Williamson AL
Virol J; 2012 Aug; 9():164. PubMed ID: 22897914
[TBL] [Abstract][Full Text] [Related]
54. Cervical and oral human papillomavirus types in HIV-1 positive and negative women with cervical disease in South Africa.
Marais DJ; Passmore JA; Denny L; Sampson C; Allan BR; Williamson AL
J Med Virol; 2008 Jun; 80(6):953-9. PubMed ID: 18428143
[TBL] [Abstract][Full Text] [Related]
55. Introducing human papillomavirus vaccines into the health system in South Africa.
Botha MH; Dochez C
Vaccine; 2012 Sep; 30 Suppl 3():C28-34. PubMed ID: 22939017
[TBL] [Abstract][Full Text] [Related]
56. Infection with human papillomavirus and HIV among young women in Kampala, Uganda.
Banura C; Franceschi S; Doorn LJ; Arslan A; Wabwire-Mangen F; Mbidde EK; Quint W; Weiderpass E
J Infect Dis; 2008 Feb; 197(4):555-62. PubMed ID: 18237268
[TBL] [Abstract][Full Text] [Related]
57. Vaccine Effectiveness Against Prevalent Anal and Oral Human Papillomavirus Infection Among Men Who Have Sex With Men-United States, 2016-2018.
Meites E; Winer RL; Newcomb ME; Gorbach PM; Querec TD; Rudd J; Collins T; Lin J; Moore J; Remble T; Swanson F; Franz J; Bolan RK; Golden MR; Mustanski B; Crosby RA; Unger ER; Markowitz LE
J Infect Dis; 2020 Nov; 222(12):2052-2060. PubMed ID: 32504091
[TBL] [Abstract][Full Text] [Related]
58. Cervical HPV natural history among young Western Cape, South African women: The randomized control EVRI Trial.
Sudenga SL; Torres BN; Botha MH; Zeier M; Abrahamsen ME; Glashoff RH; Engelbrecht S; Schim Van der Loeff MF; Van der Laan LE; Kipping S; Taylor D; Giuliano AR
J Infect; 2016 Jan; 72(1):60-9. PubMed ID: 26476151
[TBL] [Abstract][Full Text] [Related]
59. Epidemiology and risk factors for human papillomavirus infection in a diverse sample of low-income young women.
Shikary T; Bernstein DI; Jin Y; Zimet GD; Rosenthal SL; Kahn JA
J Clin Virol; 2009 Oct; 46(2):107-11. PubMed ID: 19665924
[TBL] [Abstract][Full Text] [Related]
60. Human Papillomavirus Vaccination and Cervical Cytology Outcomes Among Urban Low-Income Minority Females.
Hofstetter AM; Ompad DC; Stockwell MS; Rosenthal SL; Soren K
JAMA Pediatr; 2016 May; 170(5):445-52. PubMed ID: 26974250
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
